NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
ID: 326889Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/326889

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-20-195.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the NIH Exploratory/Developmental Research Grant Program (Parent R21), aimed at supporting innovative research projects in their early stages. This grant program encourages the exploration of novel ideas and methodologies that could lead to significant advancements in biomedical, behavioral, and clinical research, specifically targeting projects that may involve considerable risk but have the potential for breakthrough developments. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, for-profits, and foreign entities, with funding of up to $275,000 available over a maximum project period of two years. Interested parties should note that clinical trial proposals are not accepted, and applications must be submitted by January 7, 2025, with further details available at NIH Grants. For any issues related to the funding announcement, applicants can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PA-20-195-Full-Announcement.html
    PA-20-195.html
    The National Institutes of Health (NIH) announces the NIH Exploratory/Developmental Research Grant Program (Parent R21), which supports innovative research projects in their early stages. This program encourages the exploration of novel ideas and methodologies that could lead to significant advancements in biomedical, behavioral, and clinical research. The funding opportunity invites applications distinct from traditional R01 grants and provides up to $275,000 over a maximum project period of two years. Clinical trial proposals are not accepted. Eligible applicants include higher education institutions, nonprofits, for-profits, and foreign organizations. Key dates include an open date for applications starting May 16, 2020, with an anticipated expiration date of January 8, 2025. Applications will be evaluated on their significance, investigator qualifications, innovation, approach, and environment, emphasizing the potential impact of the proposed research. Overall, this initiative seeks to foster creativity and advance scientific understanding through novel research ideas and approaches within the NIH framework.
    Similar Opportunities
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21), aimed at supporting innovative early-stage research projects in the biomedical, behavioral, and clinical fields. This funding opportunity is specifically designed for basic experimental studies involving human participants, with a focus on developing novel techniques or methodologies that can significantly advance scientific understanding. Eligible applicants, including small businesses and various institutions, can receive funding of up to $275,000 over a two-year period, with applications accepted on a rolling basis until the close date of January 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PA-20-196.html.
    NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is offering the Exploratory/Developmental Research Grant (R21), which aims to support high-risk and innovative research projects that align with the mission of advancing mental health research. This grant is specifically designed for the early stages of research that may lead to significant breakthroughs in clinical and biomedical fields related to mental health, with a funding limit of $275,000 over a two-year period. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, and tribal governments, emphasizing the importance of innovative approaches in addressing critical barriers in mental health research. Interested parties should note that applications are due by January 7, 2025, and must adhere to NIH guidelines, with further inquiries directed to grantsinfo@nih.gov.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 mechanism, aimed at fostering innovative engineering solutions to advance biomedical research. This funding opportunity encourages applications from a diverse range of organizations, including higher education institutions and nonprofits, to support exploratory projects that demonstrate feasibility and potential utility in addressing critical challenges in biomedical research and clinical care delivery, without involving clinical trials. The initiative emphasizes collaboration between quantitative and physical scientists and biomedical researchers, aiming to facilitate early-stage developments that can lead to significant advancements in medical technologies and methods. The funding ceiling is set at $275,000 over two years, with applications due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-090.html.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 funding mechanism, aimed at fostering innovative projects that address significant biomedical challenges. This funding opportunity encourages applications that explore new capabilities or improvements in biomedical research, clinical care delivery, and accessibility, with a focus on groundbreaking engineering research and collaboration across diverse scientific disciplines. Eligible applicants include higher education institutions, nonprofits, and small businesses, with a budget cap of $275,000 over two years, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-091.html.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) to support innovative research aimed at addressing minority health and health disparities in the United States. This grant invites applications for short-term exploratory projects that can either pioneer new advancements or build upon previous findings, with a maximum funding amount of $275,000 available for a two-year project period, limiting annual requests to $200,000. The program emphasizes the importance of diverse representation among applicants and encourages partnerships with relevant stakeholders, focusing on NIH-designated health disparity populations through various research methodologies. Interested applicants can find more information and submission guidelines at the provided link, with the application deadline set for May 7, 2026. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Small Grants for New Investigators to Promote Diversity in Health-Related Research" (R21 Clinical Trial Optional) to support new investigators from diverse backgrounds in conducting small research projects. This funding opportunity aims to facilitate the transition to independent research careers for individuals who have not previously secured over $125,000 in direct costs of research funding, specifically targeting those from historically underrepresented groups in biomedical research. The grants, which can last up to three years with a maximum direct cost of $125,000 annually, are intended to foster innovation and address health disparities in underserved populations. Interested applicants must submit their proposals by January 8, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.